Tyrosine Kinase Inhibitors Show Enhanced Efficacy in Cancer Treatment

Strategic Insights -

Researchers from the Birla Institute of Technology and Science have developed a new approach for delivering tyrosine kinase inhibitors (TKIs), including erlotinib and gefitinib, to cancer cells with improved efficacy. The team's gum arabic-stabilized zein nanoparticles (GA-ZNPs) formulations have shown enhanced drug delivery and anticancer efficacy, offering a promising approach for targeted cancer therapy.

Key Takeaways:

  • The study found that GA-ZNPs formulations exhibited particle sizes of 136.34 nm for erlotinib-GA-ZNPs and 163.65 nm for gefitinib-GA-ZNPs, with 86.4% and 82.9% encapsulation efficiencies, respectively.
  • The drug-loaded GA-ZNPs demonstrated sustained release, with cumulative drug release reaching 75.8% for erlotinib and 65.7% for gefitinib over 72 hours.
  • Uptake studies revealed a 2.45-2.7-fold increase in intracellular drug accumulation for GA-ZNPs formulations compared to free drugs.
  • The formulations significantly enhanced the cytotoxicity of the drugs on cancer cells, reducing the IC50 of free drugs by 1.58-2.35-fold for erlotinib and 1.8-1.9-fold for gefitinib.
  • Mechanistic studies revealed higher ROS generation and mitochondrial membrane depolarization in cells treated with GA-ZNPs formulations.

Statistics:

  • The GA-ZNPs formulations exhibited particle sizes of 136.34 nm for erlotinib-GA-ZNPs and 163.65 nm for gefitinib-GA-ZNPs.
  • The encapsulation efficiencies for erlotinib-GA-ZNPs and gefitinib-GA-ZNPs were 86.4% and 82.9%, respectively.
  • The cumulative drug release for erlotinib-GA-ZNPs and gefitinib-GA-ZNPs reached 75.8% and 65.7% over 72 hours.
  • The IC50 of free drugs was reduced by 1.58-2.35-fold for erlotinib and 1.8-1.9-fold for gefitinib with GA-ZNPs formulations.

Sources:

  • Tyrosine kinase inhibitor-loaded zein nanoparticles with enhanced drug delivery and anticancer efficacy. International Journal of Biological Macromolecules, 2025:143898.
  • Birla Institute of Technology and Science Reports Findings in Cancer (Tyrosine kinase inhibitor-loaded zein nanoparticles with enhanced drug delivery and anticancer efficacy). Nanotechnology Weekly. May 26, 2025; p 39.